News

News

Certis Oncology Collaborates with Science Exchange to Offer On-Demand Access to its Orthotopic PDX Services

Science Exchange, the leading marketplace for outsourced R&D, and Certis Oncology, a leading provider for preclinical mouse modeling and tumor banking services, announced they are working together to bring Certis’ breakthrough orthotopic PDX-based CRO services to the global research community of Science Exchange.

Certis’ Orthotopic Patient-Derived Xenografts (PDXs) provides a cost-effective model for developing new drugs to battle all types of cancers. Using the orthotopic technique, Certis scientists take a very small specimen of the human patient’s tumor and surgically implant it into the corresponding anatomic location (pancreas, liver, lung, etc.) in immunodeficient mice. Pharmaceutical and biotech companies contract with Certis to develop custom mouse models to test against all types of solid tumors to determine the effectiveness of new drugs they are developing.

“Our primary objective is to save and extend lives,” said Peter Ellman, CEO at Certis Oncology. “To help us achieve this goal, Science Exchange is providing us with the reach and support to expedite the availability of our pre-clinical and tumor banking services to companies around the world that are developing new cancer drugs.”

“Certis’s Orthotopic PDX technique has proven to rapidly grow individual patient tumors in mice at a high rate,” said Elizabeth Iorns , Ph.D., co-founder and CEO of Science Exchange. “The orthotopic models more accurately replicate human tumor growth, metastasis and response to therapy, making it more immediately clinically relevant than other models. Success with drug testing on these mice can help determine which drugs are suitable for human clinical trials.”

About Certis Oncology

Certis Oncology Solutions was formed in 2016 with the mission to provide individualized precision patient care. Certis’ oncologist-directed therapy enables oncologists to tailor and optimize therapies for patients suffering from aggressive cancers. Certis also provides pre-clinical services for pharmaceutical and biotech companies. In more than 40 published peer-reviewed studies, we have demonstrated the ability of our Orthotopic PDX tumors to grow in immunodeficient mice at a high rate and replicate patient outcomes. Certis is affiliated with leading cancer physicians from UCLA and Memorial Sloan Kettering. Follow Certis on @CertisOncologyLinkedIn and YouTube.

ABOUT THE AUTHOR
author

Gursatya "Guru" Singh

Director of Scientific Content & Marketing

Gursatya Singh, also known as "Guru", manages the development and execution of strategic marketing initiatives to improve platform providers’ visibility and user experience. He is a true guru when it comes to helping providers better advertise their research services and providing buyers with easy access to recently commercialized external innovations. Whether working as a lab researcher, publishing scientific papers, or helping start life science startups, Guru believes in making the scientific world more collaborative and connected. Guru holds a master’s degree in biotechnology from the University of Delaware. Follow him on Twitter @Gursatya.

Leave a Reply

Your email address will not be published.